Axonics price target raised to $73 from $65 at Truist

Truist raised the firm’s price target on Axonics to $73 from $65 and keeps a Buy rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.